Image not available

Baishya R et al, 2012: Management of nephrolithiasis in autosomal dominant polycystic kidney disease - A single center experience

Baishya R, Dhawan DR, Kurien A, Ganpule A, Sabnis RB, Desai MR
Department of Urology, Muljibhai Patel Urological Hospital, Nadiad, Gujarat, India


Abstract

PURPOSE: To evaluate available options for the management of nephrolithiasis in patients with autosomal dominant polycystic kidney disease (ADPKD).

MATERIALS AND METHODS: Case files of all the patients with ADPKD treated in our hospital in the last 18 years were evaluated. Their demographic details, clinical presentations, investigations, treatments, and outcomes were critically analyzed.

RESULTS: There were a total of 19 patients (23 renal units) with nephrolithiasis among 452 consecutive cases of ADPKD. Male-to-female ratio was 3.75:1. The mean age of the patients was 43.3 years (range 23 to 60 years). The most common presentations were pain and hematuria (27.7% each). Mean serum creatinine was 7.2 mg/ dl (range 0.8-18.1 mg/dl) at presentation. The mean stone size was 115 mm(2) (range 36 to 980 mm(2)). The majority of the stones were calyceal (n = 10). Ten renal units (nine patients) required intervention, while the rest were treated conservatively. Treatment offered included open nephrectomy for non-functioning infected kidney (n = 1), extracorporeal shock wave lithotripsy (ESWL, n = 3), ureterorenoscopy (URS, n = 3), and percutaneous nephrolithotomy (PCNL, n = 3). All patients undergoing URS and PCNL had complete clearance, while those undergoing ESWL had a residual stone. Two failed ESWL patients required an auxiliary procedure (retrograde intrarenal surgery, RIRS) and the other was kept under observation. Mean follow-up after treatment was 4.2 years (one month to six years). None of the patients had major complications.

CONCLUSION: Careful selection of the endourological procedure can give good results in patients of ADPKD with nephrolithiasis.

Urol Ann. 2012 Jan;4(1):29-33. doi: 10.4103/0974-7796.91618
PMID: 22346098 [PubMed] PMCID: PMC3271447

Rate this blog entry:
0
 

Comments 1

Peter Alken on Friday, 02 December 2011 06:44

There were 2 failures in the 3 patients treated with ESWL. But only 1500 shocks per session and energy below 13kV were used to prevent cyst hemorrhage.

Peter Alken

There were 2 failures in the 3 patients treated with ESWL. But only 1500 shocks per session and energy below 13kV were used to prevent cyst hemorrhage. Peter Alken
Guest
Friday, 28 July 2017
STORZ MEDICAL AG
Lohstampfestrasse 8
8274 Tägerwilen
Switzerland
Tel.: +41 (0)71 677 45 45
Fax: +41 (0)71 677 45 05

www.storzmedical.com
Personal data
Address
Contact data
Message